Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anticancer effects of imatinib via immunostimulation.

Literature DB >> 21900920

Anticancer effects of imatinib via immunostimulation.

Laurence Zitvogel, Guido Kroemer.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 21900920 DOI： 10.1038/nm.2429

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

12 in total

1. A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity.

Authors: Masayuki Okada; Souichi Adachi; Tsuyoshi Imai; Ken-ichiro Watanabe; Shin-ya Toyokuni; Masaki Ueno; Antonis S Zervos; Guido Kroemer; Tatsutoshi Nakahata
Journal: Blood Date: 2003-11-26 Impact factor: 22.113

2. Decoding cell death signals in inflammation and immunity.

Authors: Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal: Cell Date: 2010-03-19 Impact factor: 41.582

Review 3. Targeted therapy in GIST: in silico modeling for prediction of resistance.

Authors: Marco A Pierotti; Elena Tamborini; Tiziana Negri; Sabrina Pricl; Silvana Pilotti
Journal: Nat Rev Clin Oncol Date: 2011-03 Impact factor: 66.675

4. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Authors: Nicolas F Delahaye; Sylvie Rusakiewicz; Isabelle Martins; Cédric Ménard; Stephan Roux; Luc Lyonnet; Pascale Paul; Matthieu Sarabi; Nathalie Chaput; Michaela Semeraro; Véronique Minard-Colin; Vichnou Poirier-Colame; Kariman Chaba; Caroline Flament; Véronique Baud; Hélène Authier; Saadia Kerdine-Römer; Marc Pallardy; Isabelle Cremer; Laetitia Peaudecerf; Bénédita Rocha; Dominique Valteau-Couanet; Javier Celis Gutierrez; Jacques A Nunès; Frédéric Commo; Sylvie Bonvalot; Nicolas Ibrahim; Philippe Terrier; Paule Opolon; Cristina Bottino; Alessandro Moretta; Jan Tavernier; Pascal Rihet; Jean-Michel Coindre; Jean-Yves Blay; Nicolas Isambert; Jean-François Emile; Eric Vivier; Axel Lecesne; Guido Kroemer; Laurence Zitvogel
Journal: Nat Med Date: 2011-05-08 Impact factor: 53.440

5. A novel dendritic cell subset involved in tumor immunosurveillance.

Authors: Julien Taieb; Nathalie Chaput; Cédric Ménard; Lionel Apetoh; Evelyn Ullrich; Mathieu Bonmort; Marie Péquignot; Noelia Casares; Magali Terme; Caroline Flament; Paule Opolon; Yann Lecluse; Didier Métivier; Elena Tomasello; Eric Vivier; François Ghiringhelli; François Martin; David Klatzmann; Thierry Poynard; Thomas Tursz; Graça Raposo; Hideo Yagita; Bernard Ryffel; Guido Kroemer; Laurence Zitvogel
Journal: Nat Med Date: 2006-01-29 Impact factor: 53.440

6. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Authors: Christophe Borg; Magali Terme; Julien Taïeb; Cédric Ménard; Caroline Flament; Caroline Robert; Koji Maruyama; Hiro Wakasugi; Eric Angevin; Kris Thielemans; Axel Le Cesne; Véronique Chung-Scott; Vladimir Lazar; Isabelle Tchou; Florent Crépineau; François Lemoine; Jacky Bernard; Jonhantan A Fletcher; Ali Turhan; Jean-Yves Blay; Alain Spatz; Jean-François Emile; Michael C Heinrich; Salah Mécheri; Thomas Tursz; Laurence Zitvogel
Journal: J Clin Invest Date: 2004-08 Impact factor: 14.808

Review 7. Hallmarks of cancer: the next generation.

Authors: Douglas Hanahan; Robert A Weinberg
Journal: Cell Date: 2011-03-04 Impact factor: 41.582

8. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Authors: Silvia Catellani; Ivana Pierri; Marco Gobbi; Alessandro Poggi; Maria Raffaella Zocchi
Journal: PLoS One Date: 2011-04-18 Impact factor: 3.240

9. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

Authors: Vinod P Balachandran; Michael J Cavnar; Shan Zeng; Zubin M Bamboat; Lee M Ocuin; Hebroon Obaid; Eric C Sorenson; Rachel Popow; Charlotte Ariyan; Ferdinand Rossi; Peter Besmer; Tianhua Guo; Cristina R Antonescu; Takahiro Taguchi; Jianda Yuan; Jedd D Wolchok; James P Allison; Ronald P DeMatteo
Journal: Nat Med Date: 2011-08-28 Impact factor: 53.440

10. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors: François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal: J Exp Med Date: 2005-10-17 Impact factor: 14.307

6 in total

Anticancer effects of imatinib via immunostimulation.

1. A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity.

2. Decoding cell death signals in inflammation and immunity.

Review 3. Targeted therapy in GIST: in silico modeling for prediction of resistance.

4. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

5. A novel dendritic cell subset involved in tumor immunosurveillance.

6. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Review 7. Hallmarks of cancer: the next generation.

8. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

9. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

10. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

1. Resistance to c-Kit inhibitors in melanoma: insights for future therapies.

Review 2. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.

3. Treatment of hepatic carcinoma by low-frequency ultrasound and microbubbles: A case report.

Review 4. The Adverse Impact of Tumor Microenvironment on NK-Cell.

5. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib.

6. Dasatinib promotes Th1-type responses in granzyme B expressing T-cells.